AI-Enhanced Conversational Agents for Personalized Asthma Support in People With Asthma: Factors for Engagement, Value, and Efficacy in a Cross-Sectional Survey Study

人工智能增强型对话代理在哮喘患者个性化支持中的应用:一项横断面调查研究中影响参与度、价值和有效性的因素

阅读:1

Abstract

BACKGROUND: Asthma-related deaths in the United Kingdom are the highest in Europe, and only 30% of patients access basic care. There is a need for alternative approaches to reaching people with asthma to provide health education, self-management support, and better bridges to care. OBJECTIVE: This study aimed to examine patients' interest in using a chatbot for asthma and to identify factors that influence engagement. Automated conversational agents (specifically, mobile chatbots) present opportunities for providing alternative and individually tailored access to health education, self-management support, and risk self-assessment. But would patients engage with a chatbot, and what factors influence engagement? METHODS: We present results from a patient survey (N=1257) developed by a team of asthma clinicians, patients, and technology developers, conducted to identify optimal factors for efficacy, value, and engagement with an asthma chatbot. RESULTS: Results indicate that most adults with asthma (53%) are interested in using a chatbot. The patients most likely to do so are those who believe their asthma is more serious and are less confident in their self-management. Results also indicate enthusiasm for 24/7 access, personalization, and for WhatsApp (Meta) as the preferred access method (compared to app, voice assistant, SMS text messaging, or website). CONCLUSIONS: Obstacles to uptake include security and privacy concerns and skepticism of technological capabilities. We present detailed findings and consolidate these into 7 recommendations for developers to optimize the efficacy of chatbot-based health support.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。